AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY® (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody administered subcutaneously for...

CalciMedica Inc. a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and...

Hyundai Bioscience (CEO Oh Sang-gi), which is preparing for a dengue fever basket clinical trial in Brazil, announced on the 24th that it has successfully developed a 'multi-treatment drug for...

Smart Cups, the groundbreaking sustainability-driven technology company specializing in innovative precise ingredient dosing through printing, is launching a new round of fundraising goals and...

Rigaku Analytical Devices, a pioneer in developing handheld 1064 nm Raman analyzers, is pleased to announce distribution relationship Avantor, a leading provider of mission-critical products and...

Indivior PLC announced the publication of a modeling study in Frontiers in Psychiatry that predicts OPVEE (nalmefene) nasal spray (2.7 mg nalmefene, equivalent to 3 mg of nalmefene hydrochloride)...

BioMarin Pharmaceutical Inc. announced the presentation of new data from an investigator-led analysis of the Phase 2 111-205 study, which demonstrate that children with achondroplasia treated with...

MTF Biologics, a global leader in tissue-based solutions, and Centurion Therapeutics, a pioneering distributor in the medical field, today announced they have entered into a new agreement that will...

Qosina, a global supplier of OEM single-use components to the medical and pharmaceutical industries, has partnered with Polestar Technologies, a leader in optical sensing technologies since 1993,...

Immorta Bio Inc, a science-based Life Extension company announced today positive preclinical findings utilizing its senescent cell-killing immunotherapeutic product SenoVax™ in a model of non-small...

BioArctic AB's partner Eisai announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Application (sBLA) for less frequent monthly...

Agomab Therapeutics NV (‘Agomab’) announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for AGMB-447, its inhaled, small molecule inhibitor of ALK5.